Pulmatrix Corp (PULM) Operating Margin

Public company logo of Pulmatrix, Inc. (PULM)

Pulmatrix, Inc. (PULM) is developing iSPERSE-based inhalation therapies for lung pathologies, creating significant opportunities for M&A transactions. Ownership of a unique drug delivery system ensures high business scalability. The operating margin profile reflects the impact of these factors, where 0.00 captures the current state of the parameter. However, aggressive capital expenditure and uncertainty regarding the timeline for asset commercialization create serious risks.

PULM - Pulmatrix Operating Profit Ratio over the range 07/04/2022 - 11/19/2026

PULM (Pulmatrix): analytical breakdowns and indicator data

- price and consensus price forecast:
General company analysis:Pulmatrix Corp
Finished products of pulmatrix.com

Pulmatrix, Inc. (PULM) development of innovative inhalation drugs requires significant expenditures, making the control of operating efficiency before financial obligations critically important. This metric assesses the share of profit from core operations in revenue, allowing the operating income margin to determine the business model's resilience to inflationary pressure and the company's ability to maintain commercial profitability during periods of contracting demand.

Competitor analysis for Pulmatrix, Inc.

Operating Profitability haleon.com|Operating Profitability KVUE|Operating Profitability Verona Pharma (VRNA)|Jyong Biotech (MENS) - Operating Profitability Margin|Operating Margin LGND (Ligand Pharma)|Amneal Pharmaceuticals Inc - Operating Profitability|PRGO - Operating Profitability|Alvotech Corp (ALVO) - Operating Sales Margin|LQDA: Operating Margin|Operating Return on Sales glpg.com (GLPG)|Operating Profitability ANI Pharmaceuticals Inc|MNKD: Operating Profit Rate|Operating Sales Margin AMPH (Amphastar)|PCRX - Operating Return on Sales|Operating Margin SPRY (ars-pharma.com)|Operating Profit Rate TBPH|Aquestive Therapeutics, Inc. - Operating Margin|scpharmaceuticals.com - Operating Profit Ratio|Tectonic (TECX) - Operating Profitability|Operating Sales Margin Tonix Pharmaceuticals Inc.|Operating Profitability sxtchina.com|Operating Sales Margin Eupraxia Pharmaceuticals (EPRX)|Operating Margin BHST|EXOZ - Operating Return on Sales|Oramed - Operating Sales Margin|Entera Bio Ltd. (ENTX) - Operating Return on Sales|HYFT - Operating Profitability|ABVC: Operating Profitability|CPIX: Operating Margin|Quantum BioPharma Ltd. - Operating Profit Rate|FGEN (FibroGen Corp) - Operating Margin|Telomir Pharma (TELO) - Profitability of Operations|Operating Profitability Rani Therapeutics Inc (RANI)|SNYR (Synergy CHC Corp.) - Operating Profit Rate|Operating Profitability Rallybio Corporation RLYB|LEXX: Return on Sales by Operating Profit|Pheton Holdings - Operating Margin|Operating Profit Margin APM|Lyra Therapeutics, Inc. (LYRA) - Operating Profitability|Operating Return on Sales Impact BioMedical, Inc. (IBO)|Operating Profitability TNF Pharma|YCBD: Operating Profit Rate|Operating Margin PRFX|CYTO - Operating Return on Sales|Operating Profitability Lipella LIPO|Operating Profit Ratio OPTN (OptiNose, Inc.)|PIRS - Operating Profitability|Procaps (PROC) - Operating Sales Margin|PTPI: Operating Margin|Qilian International (QLI) - Operating Margin|Operating Profitability Acelyrin, Inc.|Operating Margin TFF Pharmaceuticals, Inc.